Editas Medicine Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $47M+45.5% YoYTTM through 30 Jun 2026
Net Income -$73.9MTTM through 30 Jun 2026
Free Cash Flow -$120.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -149.2% |
| Operating Margin | -394.9% |
| Net Margin | -157.3% |
Returns
-85.8%ROA
Balance Sheet Health
Debt / Equity1.96x
Current Ratio3.54x
Net Debt-$93Mnet cash position
Cash & Equivalents$181.8M
Quality Metrics
Altman Z-Score-7.92
Piotroski F-Score2 / 9
FCF Margin-256.5%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $40.5M
Diluted EPS-$0.66TTMFY2025: $-1.80
Dividend
No dividend
Capital Allocation
Capex Intensity1.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration and other R&D | $40.5M | +25.4% | View detailsThe company is pivoting to focus entirely on its in vivo gene editing pipeline, specifically EDIT-401, following the discontinuation of the reni-cel program. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.